Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

por Rafii, Saeed, Gourley, Charlie, Kumar, Rajiv, Geuna, Elena, Ang, Joo Ern, Rye, Tzyvia, Chen, Lee-May, Shapira-Frommer, Ronnie, Friedlander, Michael, Matulonis, Ursula, Greve, Jacques De, Oza, Amit M., Banerjee, Susana, Rhoda Molife, L., Gore, Martin E., Kaye, Stan B., Yap, Timothy A.
Publicado 2017